All In Biotech

Drug Trial Radar · NCT06235099

Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer

A Phase 3, Multi-Center, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Men With Biochemical Recurrence of Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

235

Actual

Start

Apr 1, 2024

Primary completion

Feb 18, 2025

Study completion Feb 18, 2025

Sponsor

Lead sponsor
Curium US LLCIndustry
Sponsor type
Industry
First posted
Jan 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent prostate cancer after radical prostatectomy or radiation therapy.

Conditions

  • Prostate Cancer
  • Prostate Adenocarcinoma
  • Biochemical Recurrence of Malignant Neoplasm of Prostate

Interventions

  • Copper Cu 64 PSMA I&TDrug

    Radiopharmaceutical PET imaging tracer injected intravenously for the detection of PSMA expression.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient-Level Correct Detection Rate (CDR)Time frame: 4 hours
  2. Region-Level Correct Localization Rate (CLR)Time frame: 4 hours

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • Providence Medical Foundation

    Fullerton, California

  • Tower Urology

    Los Angeles, California

  • VA Greater Los Angeles Healthcare System

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • University of California, Irvine

    Orange, California

  • San Francisco VA Medical Center

    San Francisco, California

  • Providence Saint John's Health Center

    Santa Monica, California

  • Stanford Hospital & Clinics

    Stanford, California

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Biogenix Molecular, LLC

    Miami, Florida

  • Florida Urology Partners

    Tampa, Florida

  • Edward Hines Jr VA Hospital

    Hines, Illinois

  • Urology of Indiana, LLC

    Carmel, Indiana

  • Indiana University Health Neuroscience Center

    Indianapolis, Indiana

  • University of Iowa

    Iowa City, Iowa

  • The University of Kansas Hospital

    Kansas City, Kansas

  • M Health Fairview University of Minnesota Medical Center

    Minneapolis, Minnesota

  • SSM Health Saint Louis University Hospital

    St Louis, Missouri

  • John Cochran VA Medical Center

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Great Plains Health, Diagnostic Imaging

    North Platte, Nebraska

  • XCancer

    Omaha, Nebraska

  • Queens Hospital Center

    Jamaica, New York

  • James J. Peters VA Medical Center

    The Bronx, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • VA Portland Health Care System

    Portland, Oregon

  • Carolina Urologic Research Center, LLC

    Myrtle Beach, South Carolina

  • University of Tennessee Medical Center

    Knoxville, Tennessee

  • Excel Diagnostics and Nuclear Oncology Center

    Houston, Texas

  • Urology San Antonio

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.